A Study of Epoetin Beta Treatment in Anemic Participants With Myelodysplastic Syndrome (MDS)

  • Neurodegenerative Disorder
Trial Status:


This trial runs in
  • Thailand
Trial Identifier:

NCT02145026 ML29005

      Show trial locations

      The source of the below information is public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc.. It has been summarised and edited into simpler language. For more information about this clinical trial see the For Expert tab on the specific ForPatients page or follow these links to https://clinicaltrials.gov and/or https://euclinicaltrials.eu and/or https://www.isrctn.com.

      The below information is taken directly from public registry websites such as ClinicalTrials.gov, EuClinicalTrials.eu, ISRCTN.com, etc., and has not been edited.

      Results Disclaimer

      Trial Summary

      This is a Phase IV, prospective, multi-center, open-label study to assess the effectiveness and safety profile of epoetin beta (Recormon®) for treatment of symptomatic anemia in adult participants associated with low/intermediate-1-risk MDS. After screening, eligible participants will be treated with epoetin beta as recommended in the approved label and international guidelines for the use of epoetin in MDS participants and the dosage will be adjusted on the basis of erythroid response.

      Hoffmann-La Roche Sponsor
      Phase 4 Phase
      NCT02145026 , ML29005 Trial Identifier
      Epoetin beta Treatments
      Myelodysplastic Syndromes Condition
      Official Title

      A Prospective Open-Label Study of the Effectiveness of Epoetin Beta for Treating Anemic Patients With Low/Intermediate-1-Risk Myelodysplastic Syndrome (MDS)

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Adult participants with low or intermediate-1 risk MDS
      • No previous treatment with hematopoietic growth factors within 3 months prior to screening
      • Symptomatic anemia (hemoglobin <10 g/dL) as determined by investigator
      • Serum erythropoietin <500 milliunits/milliliter (mU/mL) within 14 days prior to the first dose of study treatment
      • Require no red blood cell transfusion or dependent on <4 units within 8 weeks prior to screening
      • Clinically stable for at least 1 month prior to entry into the study
      • For female participants of childbearing potential and male participants with partners of childbearing potential, agreement (by participants and/or partner) to use highly effective form(s) of contraception
      Exclusion Criteria
      • Contraindications and/or known hypersensitivity to the active substance and/or any of the excipients of epoetin beta treatment
      • Poorly controlled hypertension as assessed by the investigator
      • History of Acute Myeloid Leukemia (AML) or high risk for AML
      • Administration of another investigational drug within 1 month before screening or planned during the study period
      • Previously documented evidence of Pure Red Cell Aplasia (PRCA)

      Clinical Research Explained

      Information about what clinical trials and observational studies are. Understand why you might want to take part in clinical research and why diversity in clinical research is important.

      Find out now